Shenzhen Saibaoer Biopharmaceutical

Shenzhen Saibaoer Biopharmaceutical is a Chinese biotechnology company specializing in the development and large-scale manufacture of recombinant protein therapeutics. Founded in 1999 and currently operating as a subsidiary of Harbin Pharmaceutical Group, the company focuses on high-demand biologics for hematology, oncology, and infectious diseases. Its core product portfolio includes Saibaoer, a recombinant human erythropoietin (rhEPO) for treating renal anemia, and Saibaojin, a recombinant human granulocyte colony-stimulating factor (rhG-CSF) for chemotherapy-induced neutropenia. The company maintains advanced GMP-certified production facilities in Shenzhen, supporting both domestic supply and international exports. Saibaoer is recognized as a significant player in the Chinese biopharmaceutical market, particularly for its established track record in cytokine and hormone production.